Bioptigen debuts spectral-domain OCT system for preclinical ophthalmic applications
The Envisu R4300 spectral-domain optical coherence tomography (SD-OCT) system from Bioptigen offers 800 nm depth-imaging capability and 5 µm axial resolution for imaging deep eye structures in preclinical ophthalmic research and development.
The Envisu R4300 spectral-domain optical coherence tomography (SD-OCT) system from Bioptigen (Research Triangle Park, NC) offers 800 nm depth-imaging capability and 5 µm axial resolution for imaging deep eye structures for preclinical ophthalmic research and development. The system can image an entire ocular lens capsule in-vivo and the positioning of an aphakic intraocular lens (IOL).
Bioptigen Offers Deep Imaging SDOCT for Pre-Clinical Applications
New Envisu™ R4300 system provides 8 millimeter depth, 4 micrometer resolution
May 02, 2011
RESEARCH TRIANGLE PARK, N.C. – The medical imaging device company, Bioptigen Inc., has created the commercial market’s deepest spectral domain optical coherence tomography (SDOCT) imaging system for pre-clinical applications.
Called the Envisu R4300, it is the first Fourier-domain OCT system with extended depth-imaging capability in the 800-nanometers wavelength band. With an imaging depth of eight millimeters – plus better than five micrometer axial resolution – the Envisu R4300 is well suited for imaging deep eye structures for pre-clinical ophthalmic research and development.
In preliminary performance demonstrations, the Envisu R4300 captured full-range images of the anterior segment. It can image an entire ocular lens capsule in vivo, as well as the positioning of an aphakic intraocular lens.
And with its patented convertible objective lens system, the Envisu R4300 provides extended-depth, high-resolution retinal imaging for clear visualization of outer retinal structures, choroid, and deep structures of the optic nerve head. In small animal models, the Envisu R4300 provides whole-eye imaging uniquely suited to developmental biometry.
“The Envisu R4300 represents a huge milestone for ophthalmic imaging,” said Dr. Eric Buckland, president and CEO. “By providing animal researchers with full-range images of ocular structures, Bioptigen is advancing science’s understanding of the eye’s developmental biology, as well as of diseases that affect the anterior segment or vitreous. And we’re accelerating visualization of surgical procedures that require a deeper field of view than is otherwise available.”
Bioptigen unveiled its Envisu R4300 system at the Association for Research in Vision and Ophthalmology (ARVO) annual meeting taking place this week in Fort Lauderdale, Fla. The company just released a new pre-clinical software package, InVivoVue™ Miner, which automates analysis of retinal layers of mouse models.
Bioptigen originally created its proprietary Envisu non-invasive spectral domain ophthalmic imaging platform specifically for small animal imaging. The Envisu family of systems uses low-power, near-infrared light to acquire, process, display and store real-time, depth-resolved images of ocular tissues. Envisu delivers resolution 100 times finer than standard ultrasound.
Bioptigen delivers highly sophisticated ophthalmic medical imaging devices renowned for their performance and versatility. The company’s passion for collaboration and innovation enables life-changing advances in health care through the boundless potential of its revolutionary imaging technologies.
Posted by Lee Mather
Follow OptoIQ on your iPhone; download the free app here.
Subscribe now to BioOptics World magazine; it's free!